Equity · Healthcare
ARCT
NASDAQArcturus Therapeutics Holdings (ARCT)
The line runs 7.59 USD on 12 August through 9.51 USD on 9 November, on a scale from 7.5 to 17.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 274.1M USD
- Revenue, year to Dec 2025
- 82.0M USD
- EPS, diluted, year to Dec 2025
- −2.40 USD
- 52-week range
- 5.52 USD – 17 USD
- Avg volume
- 42.2K
as of Nov 9, 2026
Which funds hold Arcturus Therapeutics Holdings (ARCT)?
9 of the 45 institutional funds we track reported a Arcturus Therapeutics Holdings position for the quarter ended 30 Jun 2026 — a combined 38.8M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 2,901,635 | 19.5M USD | +4.8% |
| Two Sigma Investments | Held (±25%) | 1,091,137 | 7.3M USD | +0.9% |
| AQR Capital Management | Added | 675,014 | 4.5M USD | +318.5% |
| D. E. Shaw & Co. | Added | 392,358 | 2.6M USD | +55.7% |
| Millennium Management | Trimmed | 336,996 | 2.3M USD | −29.6% |
| Point72 Asset Management | Added | 231,582 | 1.6M USD | +262.7% |
| Marshall Wace | New position | 77,269 | 519K USD | |
| Citadel Advisors | Held (±25%) | 40,946 | 275K USD | +17.7% |
| Renaissance Technologies | Trimmed | 21,400 | 144K USD | −88.0% |
What has been filed or recorded for Arcturus Therapeutics Holdings (ARCT)?
The filings we hold for Arcturus Therapeutics Holdings, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.26 USD | Revenue $18M |
| 30 Sep 2026 | Financials | Total assets | 215.3M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 168.7M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.84 USD | Revenue $3M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.95 USD | Revenue $2M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.40 USD | Revenue $82M |
| 31 Dec 2025 | Financials | Revenue | 82.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −65.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.40 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.49 USD | Revenue $17M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.34 USD | Revenue $28M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.52 USD | Revenue $29M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.00 USD | Revenue $152M |
What do people ask about Arcturus Therapeutics Holdings (ARCT)?
What did Arcturus Therapeutics Holdings shares close at?9.51
Arcturus Therapeutics Holdings closed at 9.51 USD on 9 Nov 2026, down 8.12% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Arcturus Therapeutics Holdings’ market cap?274.1M
Arcturus Therapeutics Holdings is worth 274.1M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Arcturus Therapeutics Holdings’ revenue?82.0M
Arcturus Therapeutics Holdings reported revenue of 82.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Which funds own Arcturus Therapeutics Holdings?9 of 45
9 of the 45 funds we track reported a Arcturus Therapeutics Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Two Sigma Investments and AQR Capital Management. See Funds
When did Arcturus Therapeutics Holdings last report earnings?−0.26
Arcturus Therapeutics Holdings last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.26 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings